Suglat (ipragliflozin) / Kotobuki, EMD Serono, Astellas  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
RECORD-AMI, NCT05770687: SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Recruiting
N/A
1000
RoW
SGLT2 inhibitor, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin
Kiyuk Chang, Seoul St. Mary's Hospital, Uijeongbu St. Mary Hospital, Incheon St.Mary's Hospital, Daejeon St. Mary's hospital, Bucheon St. Mary's Hospital, St Vincent's Hospital, Yeouido St. Mary's Hospital, Sejong General Hospital, Pusan National University Hospital, Andong Hospital, Chungnam National University Hospital, St. Carollo General Hospital, Pusan National University Yangsan Hospital, Kyungpook National University Hospital, Jeju National University Hospital, Korea University Anam Hospital, Inje University
Myocardial Infarction, Diabetes Mellitus, Type 2
12/25
12/26

Download Options